Literature DB >> 21272601

An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus.

Yasuko Hatta1, Masato Hatta, Pamuk Bilsel, Gabriele Neumann, Yoshihiro Kawaoka.   

Abstract

The 2009 influenza pandemic brought home the importance of vaccines in infection control. Previously, we demonstrated an M2 cytoplasmic tail mutant H5N1 influenza virus could serve as a live-attenuated vaccine. Here, we adapted that strategy, generating a mutant pandemic (H1N1) 2009 virus that grew well in cell culture, but replicated less well in mice than did wild-type virus. The mutant virus elicited sterile immunity in mice, completely protecting them from challenge with a pandemic (H1N1) 2009 virus. Our results indicate that M2 cytoplasmic tail mutants are suitable for live-attenuated vaccines against pandemic viruses.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21272601      PMCID: PMC3132197          DOI: 10.1016/j.vaccine.2011.01.023

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

Review 1.  Unpacking the incoming influenza virus.

Authors:  A Helenius
Journal:  Cell       Date:  1992-05-15       Impact factor: 41.582

2.  Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production.

Authors:  Matthew F McCown; Andrew Pekosz
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging.

Authors:  Matthew F McCown; Andrew Pekosz
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly.

Authors:  Kiyoko Iwatsuki-Horimoto; Taisuke Horimoto; Takeshi Noda; Maki Kiso; Junko Maeda; Shinji Watanabe; Yukiko Muramoto; Ken Fujii; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Comparative efficacy of inactivated and live attenuated influenza vaccines.

Authors:  Arnold S Monto; Suzanne E Ohmit; Joshua G Petrie; Emileigh Johnson; Rachel Truscon; Esther Teich; Judy Rotthoff; Matthew Boulton; John C Victor
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

6.  Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants.

Authors:  Tokiko Watanabe; Shinji Watanabe; Jin Hyun Kim; Masato Hatta; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

7.  Influenza virus M2 protein has ion channel activity.

Authors:  L H Pinto; L J Holsinger; R A Lamb
Journal:  Cell       Date:  1992-05-01       Impact factor: 41.582

8.  Emergence of a novel swine-origin influenza A (H1N1) virus in humans.

Authors:  Fatimah S Dawood; Seema Jain; Lyn Finelli; Michael W Shaw; Stephen Lindstrom; Rebecca J Garten; Larisa V Gubareva; Xiyan Xu; Carolyn B Bridges; Timothy M Uyeki
Journal:  N Engl J Med       Date:  2009-05-07       Impact factor: 91.245

9.  Influenza A virus lacking M2 protein as a live attenuated vaccine.

Authors:  Shinji Watanabe; Tokiko Watanabe; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

10.  In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses.

Authors:  Yasushi Itoh; Kyoko Shinya; Maki Kiso; Tokiko Watanabe; Yoshihiro Sakoda; Masato Hatta; Yukiko Muramoto; Daisuke Tamura; Yuko Sakai-Tagawa; Takeshi Noda; Saori Sakabe; Masaki Imai; Yasuko Hatta; Shinji Watanabe; Chengjun Li; Shinya Yamada; Ken Fujii; Shin Murakami; Hirotaka Imai; Satoshi Kakugawa; Mutsumi Ito; Ryo Takano; Kiyoko Iwatsuki-Horimoto; Masayuki Shimojima; Taisuke Horimoto; Hideo Goto; Kei Takahashi; Akiko Makino; Hirohito Ishigaki; Misako Nakayama; Masatoshi Okamatsu; Kazuo Takahashi; David Warshauer; Peter A Shult; Reiko Saito; Hiroshi Suzuki; Yousuke Furuta; Makoto Yamashita; Keiko Mitamura; Kunio Nakano; Morio Nakamura; Rebecca Brockman-Schneider; Hiroshi Mitamura; Masahiko Yamazaki; Norio Sugaya; M Suresh; Makoto Ozawa; Gabriele Neumann; James Gern; Hiroshi Kida; Kazumasa Ogasawara; Yoshihiro Kawaoka
Journal:  Nature       Date:  2009-08-20       Impact factor: 49.962

View more
  8 in total

1.  Tyr82 Amino Acid Mutation in PB1 Polymerase Induces an Influenza Virus Mutator Phenotype.

Authors:  Tadasuke Naito; Kazumasa Shirai; Kotaro Mori; Hidetaka Muratsu; Hiroshi Ushirogawa; Ryosuke L Ohniwa; Kousuke Hanada; Mineki Saito
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

2.  Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.

Authors:  Michael J Moser; Yasuko Hatta; Claudia Gabaglia; Adriana Sanchez; Peter Dias; Sally Sarawar; Yoshihiro Kawaoka; Masato Hatta; Gabriele Neumann; Pamuk Bilsel
Journal:  Vaccine       Date:  2019-07-04       Impact factor: 3.641

3.  M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice.

Authors:  Sally Sarawar; Yasuko Hatta; Shinji Watanabe; Peter Dias; Gabriele Neumann; Yoshihiro Kawaoka; Pamuk Bilsel
Journal:  Vaccine       Date:  2016-09-03       Impact factor: 3.641

Review 4.  Novel Approaches for The Development of Live Attenuated Influenza Vaccines.

Authors:  Pilar Blanco-Lobo; Aitor Nogales; Laura Rodríguez; Luis Martínez-Sobrido
Journal:  Viruses       Date:  2019-02-22       Impact factor: 5.048

5.  Safety and Immunogenicity of M2-Deficient, Single Replication, Live Influenza Vaccine (M2SR) in Adults.

Authors:  Joseph Eiden; Gilad Gordon; Carlos Fierro; Renee Herber; Roger Aitchison; Robert Belshe; Harry Greenberg; Daniel Hoft; Yasuko Hatta; Michael J Moser; Magdalena Tary-Lehmann; Yoshihiro Kawaoka; Gabriele Neumann; Paul Radspinner; Pamuk Bilsel
Journal:  Vaccines (Basel)       Date:  2021-11-24

6.  Principles underlying rational design of live attenuated influenza vaccines.

Authors:  Yo Han Jang; Baik-Lin Seong
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31

Review 7.  Influenza vaccines: a moving interdisciplinary field.

Authors:  Michael Schotsaert; Adolfo García-Sastre
Journal:  Viruses       Date:  2014-10-09       Impact factor: 5.048

8.  M2-Deficient Single-Replication Influenza Vaccine-Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain.

Authors:  Joseph Eiden; Bram Volckaert; Oleg Rudenko; Roger Aitchison; Renee Herber; Robert Belshe; Harry Greenberg; Kathleen Coelingh; David Marshall; Yoshihiro Kawaoka; Gabriele Neumann; Pamuk Bilsel
Journal:  J Infect Dis       Date:  2022-08-12       Impact factor: 7.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.